Perceive Biotherapeutics is advancing a deep and diversified pipeline of targets and treatment modalities in multiple therapeutic verticals, with lead pipeline programs in ophthalmology. Perceive was founded on compelling research elucidating two novel protective biologies for treating retinal blindness, developed from foundational collaborations in genetic science and target validation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/23 | $78,000,000 | Series B |
Braidwell Catalio Capital Deerfield Management Company, L.P. Johnson & Johnson Innovation  | undisclosed |
